AU759964B2 - Liposomal compositions and methods of using them - Google Patents
Liposomal compositions and methods of using them Download PDFInfo
- Publication number
- AU759964B2 AU759964B2 AU75956/96A AU7595696A AU759964B2 AU 759964 B2 AU759964 B2 AU 759964B2 AU 75956/96 A AU75956/96 A AU 75956/96A AU 7595696 A AU7595696 A AU 7595696A AU 759964 B2 AU759964 B2 AU 759964B2
- Authority
- AU
- Australia
- Prior art keywords
- cholesterol
- condition
- disease
- administration
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 131
- 239000000203 mixture Substances 0.000 title claims description 79
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 437
- 235000012000 cholesterol Nutrition 0.000 claims description 206
- 239000002502 liposome Substances 0.000 claims description 189
- 150000002632 lipids Chemical class 0.000 claims description 132
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 111
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 111
- 239000000370 acceptor Substances 0.000 claims description 104
- 230000002440 hepatic effect Effects 0.000 claims description 101
- 150000003904 phospholipids Chemical class 0.000 claims description 91
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 65
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 65
- 102000004895 Lipoproteins Human genes 0.000 claims description 63
- 108090001030 Lipoproteins Proteins 0.000 claims description 63
- 201000010099 disease Diseases 0.000 claims description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 230000002093 peripheral effect Effects 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 40
- 229930182558 Sterol Natural products 0.000 claims description 38
- 235000003702 sterols Nutrition 0.000 claims description 38
- 150000003432 sterols Chemical class 0.000 claims description 36
- 230000000923 atherogenic effect Effects 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 30
- 239000012528 membrane Substances 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 26
- 201000001320 Atherosclerosis Diseases 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 230000003902 lesion Effects 0.000 claims description 22
- 230000003647 oxidation Effects 0.000 claims description 22
- 238000007254 oxidation reaction Methods 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 230000000747 cardiac effect Effects 0.000 claims description 20
- 101150037123 APOE gene Proteins 0.000 claims description 19
- 101100216294 Danio rerio apoeb gene Proteins 0.000 claims description 19
- 210000000056 organ Anatomy 0.000 claims description 19
- 238000002399 angioplasty Methods 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 16
- 238000000502 dialysis Methods 0.000 claims description 16
- 230000001105 regulatory effect Effects 0.000 claims description 16
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 9
- 230000004792 oxidative damage Effects 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 230000003143 atherosclerotic effect Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 5
- 206010061216 Infarction Diseases 0.000 claims description 5
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 5
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 5
- 230000032677 cell aging Effects 0.000 claims description 5
- 230000007574 infarction Effects 0.000 claims description 5
- 238000001361 intraarterial administration Methods 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 230000036262 stenosis Effects 0.000 claims description 5
- 208000037804 stenosis Diseases 0.000 claims description 5
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims description 4
- 101800002011 Amphipathic peptide Proteins 0.000 claims description 3
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 4
- 230000005856 abnormality Effects 0.000 claims 4
- 230000017531 blood circulation Effects 0.000 claims 4
- 230000000052 comparative effect Effects 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 2
- 229960001231 choline Drugs 0.000 claims 2
- 241000045500 Diseae Species 0.000 claims 1
- 239000003643 water by type Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 107
- 210000004185 liver Anatomy 0.000 description 67
- 210000001519 tissue Anatomy 0.000 description 65
- 239000000463 material Substances 0.000 description 63
- 238000003556 assay Methods 0.000 description 60
- 239000007924 injection Substances 0.000 description 60
- 238000002347 injection Methods 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 53
- 239000002245 particle Substances 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 230000031154 cholesterol homeostasis Effects 0.000 description 37
- 239000011780 sodium chloride Substances 0.000 description 37
- 108020004999 messenger RNA Proteins 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 31
- 238000001727 in vivo Methods 0.000 description 29
- 230000004044 response Effects 0.000 description 29
- 230000009931 harmful effect Effects 0.000 description 28
- 108010001831 LDL receptors Proteins 0.000 description 27
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 27
- 230000036470 plasma concentration Effects 0.000 description 27
- 241000283973 Oryctolagus cuniculus Species 0.000 description 26
- -1 cholesteryl ester Chemical class 0.000 description 26
- 210000004738 parenchymal cell Anatomy 0.000 description 25
- 210000004379 membrane Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 22
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 230000003511 endothelial effect Effects 0.000 description 19
- 238000005259 measurement Methods 0.000 description 19
- 230000032258 transport Effects 0.000 description 19
- 230000001276 controlling effect Effects 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 230000001976 improved effect Effects 0.000 description 17
- 239000000839 emulsion Substances 0.000 description 15
- 230000002441 reversible effect Effects 0.000 description 14
- 230000001629 suppression Effects 0.000 description 14
- 230000004075 alteration Effects 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 11
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 210000001865 kupffer cell Anatomy 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 9
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 9
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 230000003915 cell function Effects 0.000 description 7
- 238000011260 co-administration Methods 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 101710095342 Apolipoprotein B Proteins 0.000 description 6
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000004219 arterial function Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003613 bile acid Substances 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 6
- 230000002040 relaxant effect Effects 0.000 description 6
- 108010068815 steroid hormone 7-alpha-hydroxylase Proteins 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 5
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 5
- 229940097362 cyclodextrins Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001631 haemodialysis Methods 0.000 description 5
- 230000000322 hemodialysis Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 4
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 150000001840 cholesterol esters Chemical class 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229960002965 pravastatin Drugs 0.000 description 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 101150102415 Apob gene Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000006410 Apoproteins Human genes 0.000 description 3
- 108010083590 Apoproteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000002190 fatty acyls Chemical group 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000002691 unilamellar liposome Substances 0.000 description 3
- 230000004218 vascular function Effects 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- YIKKMWSQVKJCOP-ABXCMAEBSA-N 7-ketocholesterol Chemical compound C1C[C@H](O)CC2=CC(=O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCCC(C)C)[C@@]4(C)CC[C@@H]3[C@]21C YIKKMWSQVKJCOP-ABXCMAEBSA-N 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 2
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 2
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 108010064635 HDL cholesteryl ester Proteins 0.000 description 2
- 102100028909 Heterogeneous nuclear ribonucleoprotein K Human genes 0.000 description 2
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102000004264 Osteopontin Human genes 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 102100026966 Thrombomodulin Human genes 0.000 description 2
- 108010079274 Thrombomodulin Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008568 cell cell communication Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000009716 hepatic expression Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008102 immune modulation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- UYLSRAUTYHWBOU-OMBIIZNESA-N (3s,8s,9s,10r,13r,14s,17r)-3-hexadecoxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCCCCCCCCCCCCC)C1 UYLSRAUTYHWBOU-OMBIIZNESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 0 CC1(*)C=CC=CC1 Chemical compound CC1(*)C=CC=CC1 0.000 description 1
- 101150069040 CETP gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- YCUVUDODLRLVIC-UHFFFAOYSA-N Sudan black B Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1N=NC(C1=CC=CC=C11)=CC=C1N=NC1=CC=CC=C1 YCUVUDODLRLVIC-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- 230000006493 arterial relaxation Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000006495 endothelial-dependent arterial relaxation Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000019138 food restriction Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000022275 macrophage chemotaxis Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000007814 microscopic assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000028550 monocyte chemotaxis Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000020280 negative regulation of antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000030505 negative regulation of chemotaxis Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000012006 phospholipid homeostasis Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008348 synthetic phosphatidyl choline Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1619—Sampled collection of used dialysate, i.e. obviating the need for recovery of whole dialysate quantity for post-dialysis analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3427—Substitution fluid path back through the membrane, e.g. by inverted trans-membrane pressure [TMP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3424—Substitution fluid path
- A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003200612A AU2003200612B2 (en) | 1995-10-11 | 2003-02-21 | Liposomal compositions and methods of using them |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US509095P | 1995-10-11 | 1995-10-11 | |
| US60/005090 | 1995-10-11 | ||
| US728705 | 1996-10-11 | ||
| PCT/US1996/016388 WO1997013501A1 (en) | 1995-10-11 | 1996-10-11 | Liposomal compositions and methods of using them |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003200612A Division AU2003200612B2 (en) | 1995-10-11 | 2003-02-21 | Liposomal compositions and methods of using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7595696A AU7595696A (en) | 1997-04-30 |
| AU759964B2 true AU759964B2 (en) | 2003-05-01 |
Family
ID=21714125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU75956/96A Ceased AU759964B2 (en) | 1995-10-11 | 1996-10-11 | Liposomal compositions and methods of using them |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US5858400A (enExample) |
| EP (1) | EP0863748A4 (enExample) |
| JP (1) | JP2002515856A (enExample) |
| CN (1) | CN1119145C (enExample) |
| AU (1) | AU759964B2 (enExample) |
| CA (1) | CA2231547A1 (enExample) |
| EA (1) | EA199800279A1 (enExample) |
| MX (1) | MXPA98002791A (enExample) |
| WO (1) | WO1997013501A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5746223A (en) | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
| US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| US6312719B1 (en) | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US5858400A (en) * | 1995-10-11 | 1999-01-12 | Talaria Therapeutics, Inc. | Method of suppressing a rise in LDL concentrations after administration of an agent having small acceptors |
| WO1997026870A1 (en) * | 1996-01-26 | 1997-07-31 | California Institute Of Technology | Sol-gel encapsulation of lipid vesicles, lipid membranes and proteins |
| US6569147B1 (en) * | 1996-07-26 | 2003-05-27 | Kensey Nash Corporation | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes |
| GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
| WO1998042327A2 (en) * | 1997-03-24 | 1998-10-01 | Cote Gilles | Vascular remodeling agent |
| US6524613B1 (en) * | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| ES2211151T3 (es) | 1998-08-19 | 2004-07-01 | Skyepharma Canada Inc. | Dispersiones acuosas inyectables de propofol. |
| CA2368234A1 (en) * | 1999-03-26 | 2000-10-05 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
| EP1473042B1 (en) * | 1999-03-26 | 2006-06-21 | City of Hope | Screening for FXR receptor modulators |
| US20020132223A1 (en) * | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| AU773385B2 (en) * | 1999-05-14 | 2004-05-27 | Esperion Luv Development, Inc. | Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| US6586189B2 (en) | 1999-06-18 | 2003-07-01 | City Of Hope | Screening method for PPAR-γ ligands |
| US6548739B2 (en) | 1999-06-18 | 2003-04-15 | City Of Hope | Method for activating peroxisome proliferator activated receptor-γ |
| US20030170643A1 (en) * | 1999-10-26 | 2003-09-11 | Edward Fisher | Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
| JP2003528889A (ja) * | 2000-03-24 | 2003-09-30 | シティ・オブ・ホープ | Ｓｘｒ活性の改変により薬物クリアランス機序を調節する方法 |
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| DE10117043A1 (de) * | 2001-04-05 | 2002-11-07 | Gerhard Puetz | Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen |
| NL1018354C2 (nl) * | 2001-06-21 | 2002-12-30 | Kokbing Lo | Inrichting voor het toedienen van een behandelingsvloeistof en het gebruik van een dergelijke inrichting voor het locaal in een orgaan bestrijden van kanker. |
| CA2457006A1 (en) * | 2001-08-06 | 2003-02-20 | Robert Morvillo | Integral reversing and trim deflector and control mechanism |
| US20050260256A1 (en) * | 2001-09-28 | 2005-11-24 | Hill Knut R | Methods and apparatus for extrusion of vesicles at high pressure |
| CA2460787A1 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| NZ532348A (en) | 2001-10-19 | 2006-06-30 | Vascular Biogenics Ltd | Polynucleotide constructs comprising ligand binding domains, effector domains of apoptosis signaling molecules and a promoter or enhancer and their use in gene therapy |
| US20030077310A1 (en) | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| US20050058698A1 (en) * | 2002-01-21 | 2005-03-17 | Nolan Yvonne Mairead | Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease |
| GB0207653D0 (en) | 2002-04-03 | 2002-05-15 | Lamellar Therapeutics Ltd | Methods of using lamellar bodies for therapeutic purposes |
| US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| PL374126A1 (en) * | 2002-05-17 | 2005-10-03 | Esperion Therapeutics, Inc. | Methods and copositions for the treatment of ischemic reperfusion |
| US7153286B2 (en) | 2002-05-24 | 2006-12-26 | Baxter International Inc. | Automated dialysis system |
| US7175606B2 (en) | 2002-05-24 | 2007-02-13 | Baxter International Inc. | Disposable medical fluid unit having rigid frame |
| US7238164B2 (en) | 2002-07-19 | 2007-07-03 | Baxter International Inc. | Systems, methods and apparatuses for pumping cassette-based therapies |
| US20040110803A1 (en) * | 2002-09-13 | 2004-06-10 | Hossein Dovlatabadi | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels |
| EP1596828B1 (en) * | 2003-02-14 | 2011-12-28 | Children's Hospital & Research Center at Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
| WO2005068020A1 (en) * | 2004-01-02 | 2005-07-28 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
| JP2007531537A (ja) * | 2004-04-06 | 2007-11-08 | セダーズ−シナイ メディカル センター | アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置 |
| WO2006006169A2 (en) * | 2004-07-14 | 2006-01-19 | By-Pass, Inc. | Material delivery system |
| DE102005045152A1 (de) * | 2005-09-21 | 2007-03-22 | Stremmel, Wolfgang, Prof. Dr. | Verwendung von therapeutisch wirksamen Lipiden nebst Verfahren zur Herstellung von Organ-/Gewebe-spezifischen therapeutisch wirksamen Lipiden |
| KR100752414B1 (ko) | 2006-09-15 | 2007-08-28 | 주식회사 뉴하트바이오 | Ｐｓａｆ 인공 간 시스템 |
| US20080140001A1 (en) * | 2006-12-12 | 2008-06-12 | By-Pass Inc. | Fluid Delivery Apparatus And Methods |
| US20080181928A1 (en) * | 2006-12-22 | 2008-07-31 | Miv Therapeutics, Inc. | Coatings for implantable medical devices for liposome delivery |
| CN101244089B (zh) | 2007-02-16 | 2013-09-25 | 信谊药厂 | 嗜酸乳杆菌/粪肠球菌培养基、制剂及其工艺 |
| CN101244090B (zh) | 2007-02-16 | 2011-12-28 | 信谊药厂 | 长型双岐杆菌培养基、制剂及其工艺 |
| US8512553B2 (en) | 2007-07-05 | 2013-08-20 | Baxter International Inc. | Extracorporeal dialysis ready peritoneal dialysis machine |
| US8068693B2 (en) * | 2007-07-18 | 2011-11-29 | Samsung Electronics Co., Ltd. | Method for constructing a composite image |
| US8717412B2 (en) * | 2007-07-18 | 2014-05-06 | Samsung Electronics Co., Ltd. | Panoramic image production |
| US20090226501A1 (en) * | 2007-12-07 | 2009-09-10 | Boston Scientific Scimed, Inc. | Drug coated stent with endosome-disrupting conjugate |
| DE102008010691A1 (de) * | 2008-02-22 | 2009-08-27 | Universität Rostock | Bioäquivalenzdialyse |
| US8882700B2 (en) | 2008-05-02 | 2014-11-11 | Baxter International Inc. | Smart patient transfer set for peritoneal dialysis |
| US9348975B2 (en) | 2008-05-02 | 2016-05-24 | Baxter International Inc. | Optimizing therapy outcomes for peritoneal dialysis |
| WO2009158678A1 (en) | 2008-06-27 | 2009-12-30 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use therefor |
| US8062513B2 (en) | 2008-07-09 | 2011-11-22 | Baxter International Inc. | Dialysis system and machine having therapy prescription recall |
| US9514283B2 (en) | 2008-07-09 | 2016-12-06 | Baxter International Inc. | Dialysis system having inventory management including online dextrose mixing |
| US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
| US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
| WO2010088512A1 (en) | 2009-01-30 | 2010-08-05 | Baxter International Inc. | Transfer sets for therapy optimization |
| US8282829B2 (en) * | 2009-05-20 | 2012-10-09 | Baxter International Inc. | System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology |
| US9020827B2 (en) * | 2009-10-16 | 2015-04-28 | Baxter International Inc. | Peritoneal dialysis optimized using a patient hand-held scanning device |
| WO2011112883A1 (en) * | 2010-03-12 | 2011-09-15 | The Regents Of The University Of California | Triggered cargo release from nanoparticle stabilized liposomes |
| EP2695606A1 (en) * | 2012-08-09 | 2014-02-12 | ETH Zürich | Liposome composition for peritoneal dialysis |
| US9440017B2 (en) | 2013-03-14 | 2016-09-13 | Baxter International Inc. | System and method for performing alternative and sequential blood and peritoneal dialysis modalities |
| US20190224124A1 (en) * | 2016-09-01 | 2019-07-25 | Kevin Jon Williams | Methods and Kits for Reducing the Susceptibility of Lipoprotein Particles to Atherogenic Aggregation Induced by Arterial-Wall Enzymes |
| US10821133B2 (en) * | 2017-12-28 | 2020-11-03 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| US11723865B2 (en) | 2017-02-08 | 2023-08-15 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
| US11541005B2 (en) * | 2017-02-08 | 2023-01-03 | New Hope Research Foundation, Inc. | Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord |
| CN109092262B (zh) * | 2018-08-28 | 2019-07-05 | 广州达济医学科技有限公司 | 低密度脂蛋白吸附微球及制备方法和吸附材料 |
| CN111420122A (zh) * | 2020-04-30 | 2020-07-17 | 山东隽秀生物科技股份有限公司 | 一种可诱导骨再生的生物膜及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US548961A (en) * | 1895-10-29 | Machine for removing stems from tobacco-leaves | ||
| JPS5348976A (en) * | 1976-10-18 | 1978-05-02 | Nippon Zeon Co Ltd | Mass transfer apparatus of hollow fiber type |
| US4247393A (en) * | 1979-01-11 | 1981-01-27 | Wallace Richard A | Hemodialysis assist device |
| EP0180720B1 (de) * | 1981-09-10 | 1990-06-13 | B. Braun-SSC AG | Vorrichtung zur selektiven extrakorporalen Präzipation von Low Density Lipoprotenen aus Vollserum oder Plasma |
| US4532089A (en) * | 1984-01-14 | 1985-07-30 | Northwestern University | Method of preparing giant size liposomes |
| US4978654A (en) * | 1984-04-16 | 1990-12-18 | Board Of Regents, The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| US4663167A (en) * | 1984-04-16 | 1987-05-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
| US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
| US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
| US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
| US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| WO1991004019A1 (en) * | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
| US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE4018767A1 (de) * | 1990-06-12 | 1991-12-19 | Braun Melsungen Ag | Wirkstofffreie liposomen zur behandlung von atherosklerose |
| US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
| US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
| US5219888A (en) * | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
| US5250060A (en) * | 1992-06-26 | 1993-10-05 | Carbo Paul L | Angioplasty apparatus |
| AU1751795A (en) * | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
| US5622715A (en) * | 1994-06-10 | 1997-04-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of improving renal function |
| US5489611A (en) * | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
| US5741514A (en) * | 1995-08-31 | 1998-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for reducing serum lipoprotein(a) concentration |
| US5858400A (en) * | 1995-10-11 | 1999-01-12 | Talaria Therapeutics, Inc. | Method of suppressing a rise in LDL concentrations after administration of an agent having small acceptors |
-
1996
- 1996-10-11 US US08/731,257 patent/US5858400A/en not_active Expired - Fee Related
- 1996-10-11 WO PCT/US1996/016388 patent/WO1997013501A1/en not_active Ceased
- 1996-10-11 CN CN96198729A patent/CN1119145C/zh not_active Expired - Fee Related
- 1996-10-11 JP JP51526397A patent/JP2002515856A/ja not_active Ceased
- 1996-10-11 MX MXPA98002791A patent/MXPA98002791A/es not_active Application Discontinuation
- 1996-10-11 US US08/728,697 patent/US5736157A/en not_active Expired - Fee Related
- 1996-10-11 US US08/728,705 patent/US5843474A/en not_active Expired - Fee Related
- 1996-10-11 AU AU75956/96A patent/AU759964B2/en not_active Ceased
- 1996-10-11 EA EA199800279A patent/EA199800279A1/ru unknown
- 1996-10-11 CA CA002231547A patent/CA2231547A1/en not_active Abandoned
- 1996-10-11 EP EP96938625A patent/EP0863748A4/en not_active Withdrawn
- 1996-10-11 US US08/731,256 patent/US6080422A/en not_active Expired - Fee Related
-
1997
- 1997-05-02 US US08/850,921 patent/US5948435A/en not_active Expired - Fee Related
-
1998
- 1998-04-15 US US09/060,611 patent/US20010009670A1/en not_active Abandoned
- 1998-05-04 US US09/071,980 patent/US20020041894A1/en not_active Abandoned
- 1998-09-30 US US09/164,101 patent/US20020064553A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6080422A (en) | 2000-06-27 |
| EA199800279A1 (ru) | 1999-04-29 |
| AU7595696A (en) | 1997-04-30 |
| US20020064553A1 (en) | 2002-05-30 |
| US20020041894A1 (en) | 2002-04-11 |
| US20010009670A1 (en) | 2001-07-26 |
| JP2002515856A (ja) | 2002-05-28 |
| EP0863748A1 (en) | 1998-09-16 |
| CN1228018A (zh) | 1999-09-08 |
| MXPA98002791A (es) | 2004-09-07 |
| US5736157A (en) | 1998-04-07 |
| EP0863748A4 (en) | 1999-11-03 |
| US5843474A (en) | 1998-12-01 |
| WO1997013501A1 (en) | 1997-04-17 |
| US5948435A (en) | 1999-09-07 |
| CN1119145C (zh) | 2003-08-27 |
| CA2231547A1 (en) | 1997-04-17 |
| US5858400A (en) | 1999-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU759964B2 (en) | Liposomal compositions and methods of using them | |
| US5746223A (en) | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis | |
| US6773719B2 (en) | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias | |
| AU773385B2 (en) | Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto | |
| US7101570B2 (en) | Liposome compositions and methods for the treatment of atherosclerosis | |
| US5914311A (en) | Method for reducing serum lipoprotein (A) concentration | |
| ZA200407947B (en) | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease | |
| Borensztajn et al. | Uptake of chylomicron remnants by the liver: further evidence for the modulating role of phospholipids. | |
| JP2004505035A (ja) | 荷電脂質組成物及びその使用方法 | |
| Williams et al. | Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. | |
| AU2003200612B2 (en) | Liposomal compositions and methods of using them | |
| US20020022053A1 (en) | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions and kit related thereto | |
| Donner et al. | Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis | |
| HAMILTON JR | Postheparin plasma lipase from the hepatic circulation | |
| Cham | Not All “BAD” Cholesterol Carriers Are Necessarily Bad and Not All “GOOD” Cholesterol Carriers Are as Good as Can Be: Plasma Delipidation, a Non-Pharmacological Treatment for Atherosclerosis | |
| US20050008662A1 (en) | Use of IV emulsions with different triglyceride composition, particle size and apolipoprotein E for targeted tissue delivery of hydrophobic compounds | |
| Pitha et al. | Triglycerides, remnant lipoprotein particles and preclinical atherosclerosis in the Czech population | |
| IL123509A (en) | Therapeutic lipoprotein composition containing lipid vesicles which bind apoproteins and uses therof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: ESPERIOS LUV DEVELOPMENT, INC. Free format text: FORMER NAME: TALARIA THERAPEUTICS, INC. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND SECOND PRIORITY DETAILS TO READ: 728705 US 19961011 |
|
| TC | Change of applicant's name (sec. 104) |
Owner name: ESPERIOS LUV DEVELOPMENT, INC. Free format text: FORMER NAME: ESPERIOS LUV DEVELOPMENT, INC. |
|
| TH | Corrigenda |
Free format text: IN VOL 17, NO 17, PAGE(S) 541 UNDER THE HEADING CHANGE OF NAME(S) OF APPLICANT(S), SECTION 104 THE NAME OF THE APPLICANT IN REGARD TO PATENT APPLICATION NO. 759964 SHOULD READ: ESPERION LUV DEVELOPMENT, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |